Healthcare, Pharma & Life Sciences

Isomab Review Clears Cancer, Eye Safety Fears for Angiogenic Heart Therapies

Image
Isomab Review Clears Cancer, Eye Safety Fears for Angiogenic Heart Therapies

Nottingham – September 10, 2026 -- Isomab Ltd has published a systematic review showing no increased cancer or retinopathy risk from pro-angiogenic therapies for coronary artery disease, removing a two-decade safety barrier that has constrained development across the field.

Review of 636 patients finds malignancy rates below population norms

The analysis covered 11 clinical studies conducted between 2002 and 2024, spanning 636 patients with angina or peripheral artery disease -- 441 receiving pro-angiogenic therapy and 195 on placebo -- with follow-up periods ranging from two to 12 years. Mean malignancy incidence was 0.84 per 100 patient-years for the treatment group versus 0.72 for placebo, both figures falling below the age-matched population rate of 1.0 per 100 patient-years. Retinal events were rare in both cohorts and also below population benchmarks.

Sky Labs' CART Ring Validated for AFib, Heart Failure BP Monitoring

Image
Sky Labs' CART Ring Validated for AFib, Heart Failure BP Monitoring

Munich – September 10, 2026 -- Sky Labs unveiled new clinical data at ESC Congress 2026 showing its ring-shaped blood pressure monitor CART achieved an 80% data evaluability rate in 24-hour monitoring of patients with atrial fibrillation (AFib), addressing a gap where conventional cuffs struggle with irregular pulses.

CART shows high concordance with standard ambulatory monitoring in severe heart failure patients

Professor In-Cheol Kim of Keimyung University Dongsan Hospital reported that CART, tested against conventional 24-hour ambulatory blood pressure monitoring (ABPM) in heart failure patients with a mean ejection fraction of 29%, showed high concordance and fully met European Society of Hypertension (ESH) error-margin criteria.

Sky Labs' CART Ring Shows 80% Data Accuracy in AFib, Heart Failure Trials

Image
Sky Labs' CART Ring Shows 80% Data Accuracy in AFib, Heart Failure Trials

Munich – September 10, 2026 -- Sky Labs presented new clinical trial data for its ring-based blood pressure monitor, CART, at the ESC Congress 2026 in Munich on September 7, showing an 80% data evaluability rate in continuous monitoring of atrial fibrillation (AFib) patients and high correlation with standard ambulatory blood pressure monitoring (ABPM) in severe heart failure cases.

CART achieves 80% evaluability rate in 24-hour monitoring of atrial fibrillation patients

Professor Ki-Hong Lee of Chonnam National University Hospital reported that CART's ring-based 24-hour monitoring achieved approximately 80% data evaluability in AFib patients, enabling continuous tracking of nocturnal blood pressure dipping patterns that irregular pulse rates typically disrupt for cuff-based devices.

Softcare Hosts ASN, ISO, SIS Delegation at Senegal Hygiene Plant

Image
Softcare Hosts ASN, ISO, SIS Delegation at Senegal Hygiene Plant

Dakar – September 10, 2026 -- Softcare opened its Senegal manufacturing site to a technical delegation from the Senegalese Standardization Association (ASN), the International Organization for Standardization (ISO) and the Swedish Institute for Standards (SIS), part of a stakeholder assessment targeting the country's menstrual hygiene product sector.

Delegation reviews production capacity and quality systems at Softcare's Senegal factory

The visit forms part of the project "Strengthening the Application and Compliance with International Standards for Menstrual Hygiene Products — Stakeholder Needs Assessment," which aims to map capacities, needs and constraints across Senegal's hygiene product value chain. The initiative also feeds into ongoing reinforcement of the country's National Quality Infrastructure (INQ).

AtomVie Opens $160M Radiopharma Plant, North America's Largest CDMO Site

Image
AtomVie Opens $160M Radiopharma Plant, North America's Largest CDMO Site

Hamilton, Ontario – September 09, 2026 -- AtomVie Global Radiopharma has opened a new $160 million manufacturing facility in Hamilton, Ontario, that the company calls the largest single-site radiopharmaceutical CDMO plant in North America.

New 72,300-square-foot plant multiplies manufacturing capacity tenfold

The purpose-built facility at 10 Aeropark Boulevard spans 72,300 square feet and increases AtomVie's manufacturing capacity by more than ten times its previous output. The site is designed to handle low- to high-volume production runs and supports a continuous path from early-stage clinical development through commercial-scale manufacturing.

Amwell Wins Frost & Sullivan 2026 Innovation Award for Virtual Care Platform

San Antonio – September 09, 2026 -- Frost & Sullivan has named Amwell the recipient of its 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms industry, citing the company's unified platform for connecting patients, health plan members, clinicians and partner networks.

Amwell platform now supports 90 million covered lives and 38.7 million virtual visits

Frost & Sullivan's benchmarking evaluated Amwell across strategy effectiveness and strategy execution, awarding top marks in both categories. The firm pointed to the platform's clinically integrated workflows and scalability as differentiators for organizations seeking to consolidate fragmented point solutions into a single operating layer spanning virtual primary care, urgent care, behavioral health and chronic condition management.

Inhibrx to Reveal Phase 2 HexAgon Data on INBRX-106 Sept. 8

Image
Inhibrx to Reveal Phase 2 HexAgon Data on INBRX-106 Sept. 8

San Diego – September 09, 2026 -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) will webcast primary endpoint results from the randomized, controlled Phase 2 portion of its HexAgon study on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time.

Phase 2 data will compare INBRX-106 combination therapy against pembrolizumab alone

The study evaluates INBRX-106, a hexavalent OX40 agonist, combined with pembrolizumab against pembrolizumab monotherapy as a control arm. The trial enrolled first-line, treatment-naïve patients with PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

Resonant Acquires Creapharm Bioservices to Expand EU Biobank Reach

Image
Resonant Acquires Creapharm Bioservices to Expand EU Biobank Reach

Leesburg, Va. – September 09, 2026 -- Resonant Clinical Solutions has acquired France-based Creapharm Bioservices from Myonex, expanding its cryogenic storage and biobanking capabilities across Europe to support increasingly complex cell and gene therapy trials.

Deal adds specialized cryogenic infrastructure in France

Creapharm Bioservices, headquartered in Bailly-Romainvilliers, France, provides biobanking and cryogenic storage services for biotherapeutics, advanced therapy medicinal products (ATMPs) and biological samples. Its capabilities include liquid nitrogen storage down to -196°C, mechanical freezing, cold storage, GMP-compliant sample storage and GDP-compliant custody for quality control. Financial terms of the transaction were not disclosed.

MMRO Earns URAC AI in Health Care Accreditation

Novi, Mich. – September 09, 2026 -- Managed Medical Review Organization, Inc. (MMRO) has earned URAC's Artificial Intelligence in Health Care Accreditation (Version 1.0), the first accreditation program in the U.S. to set standards for responsible AI use and development in healthcare.

MMRO built a year-long AI governance program to meet URAC's framework

The program includes responsible-use policies, risk and impact assessments addressing AI-specific data security challenges, and testing and training requirements, with formal clinical oversight from MMRO's Vice President of Clinical Programs, Jen Mongeau, DHA, MBA, MSN, RN.

Dental Service Organization Market to Hit $303B by 2031, MarketsandMarkets Says

Image
Dental Service Organization Market to Hit $303B by 2031, MarketsandMarkets Says

Delray Beach, Fla. – September 09, 2026 -- The global Dental Service Organization (DSO) market is projected to climb to USD 303.32 billion by 2031 from USD 199.88 billion in 2026, a compound annual growth rate of 8.7%, according to MarketsandMarkets.

North America leads as dentist affiliation with DSOs accelerates

North America held the largest regional share in 2025, driven by an established DSO ecosystem, a high concentration of multi-location dental practices, and rising dentist affiliation with DSO networks. Growth is further fueled by administrative complexity, staffing shortages at independent practices, and increased dental care spending.